HC Wainwright & Co. Maintains Buy on enGene Therapeutics, Lowers Price Target to $6

Benzinga Newsdesk www.benzinga.com Negative 55.8%

Neg 55.8% Neu 0% Pos 0%

HC Wainwright & Co. analyst Andres Y. Maldonado maintains enGene Therapeutics (NASDAQ:ENGN) with a Buy and lowers the price target from $25 to $6.